INHIBITION OF FLUOROURACIL-INDUCED STOMATITIS BY ORAL CRYOTHERAPY

被引:191
作者
MAHOOD, DJ
DOSE, AM
LOPRINZI, CL
VEEDER, MH
ATHMANN, LM
THERNEAU, TM
SORENSEN, JM
GAINEY, DK
MAILLIARD, JA
GUSA, NL
FINCK, GK
JOHNSON, C
GOLDBERG, RM
机构
[1] CEDAR RAPIDS ONCOL PROJECT,CEDAR RAPIDS,IA
[2] SIOUXLAND HEMATOL ONCOL ASSOCIATES,SIOUX CITY,IA
[3] ONCOL RES ASSOC,COMMUNITY CLIN ONCOL PROGRAM,DES MOINES,IA
[4] ST LUKES HOSP,COMMUNITY CLIN ONCOL PROGRAM,FARGO,ND
[5] GEISINGER CLIN & MED CTR,COMMUNITY CLIN ONCOL PROGRAM,DANVILLE,PA
[6] ILLINOIS ONCOL RES ASSOC,COMMUNITY CLIN ONCOL PROGRAM,PEORIA,IL
[7] CREIGHTON CANC CTR,OMAHA,NE
[8] DULUTH CLIN,COMMUNITY CLIN ONCOL PROGRAM,DULUTH,MN
[9] MAYO CLIN & MAYO FDN,CANC CTR STAT,ROCHESTER,MN 55905
关键词
D O I
10.1200/JCO.1991.9.3.449
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mucositis is a significant dose-limiting toxicity associated with fluorouracil (5FU), particularly when it is combined with leucovorin. We hypothesized that oral cryotherapy would cause local vasoconstriction and would temporarily decrease blood flow to the oral mucous membranes. If cryotherapy were used during the time of peak serum 5FU levels, then the oral mucous membranes would have less exposure to 5FU and thus develop less mucositis. To test this hypothesis, 95 patients scheduled to receive their first cycle of 5FU plus leucovorin were randomized to have oral cryotherapy at the time of chemotherapy administration or to serve as a control group. Subsequent mucositis was significantly reduced in the group assigned to receive cryotherapy as judged by the attending physicians (P = .0002) and by the patients themselves (P = .0001). We now routinely recommend this cryotherapy procedure for our patients receiving daily bolus 5FU plus leucovorin.
引用
收藏
页码:449 / 452
页数:4
相关论文
共 12 条
[1]  
Bookman R, 1960, Calif Med, V93, P235
[2]   EFFECT OF ACYCLOVIR ON RADIATION-INDUCED AND CHEMOTHERAPY-INDUCED MOUTH LESIONS [J].
BUBLEY, GJ ;
CHAPMAN, B ;
CHAPMAN, SK ;
CRUMPACKER, CS ;
SCHNIPPER, LE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (06) :862-865
[3]  
CHABNER BA, 1982, PHARM PRINCIPLES CAN, P183
[4]  
CLARK PI, 1985, EUR J SURG ONCOL, V11, P267
[5]  
LOPRINZI CL, 1990, CANCER, V65, P1879, DOI 10.1002/1097-0142(19900415)65:8<1879::AID-CNCR2820650834>3.0.CO
[6]  
2-8
[7]  
MORAN RG, 1989, CANCER-AM CANCER SOC, V63, P1008, DOI 10.1002/1097-0142(19890315)63:6+<1008::AID-CNCR2820631303>3.0.CO
[8]  
2-Z
[9]   BIOCHEMICAL MODULATION OF FLUOROURACIL - EVIDENCE OF SIGNIFICANT IMPROVEMENT OF SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH ADVANCED COLORECTAL-CARCINOMA [J].
POON, MA ;
OCONNELL, MJ ;
MOERTEL, CG ;
WIEAND, HS ;
CULLINAN, SA ;
EVERSON, LK ;
KROOK, JE ;
MAILLIARD, JA ;
LAURIE, JA ;
TSCHETTER, LK ;
WIESENFELD, M .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (10) :1407-1418
[10]  
RASKIN NH, 1980, HEADACHE, P1